Systems biology

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Microbiology #PCR #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

Protein Arrays for Assessment of Target Selectivity

Protein Arrays for Assessment of Target Selectivity By Professor Ian Humphery-Smith, Dr Erik Wischerhoff and Dr Ryuji Hashimoto Transforming knowledge of the human genome into a lead optimisation tool. Genomics activity has been criticised for having elucidated a plethora of potentially interesting drug… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biomarkers #Business #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomics #Genomics #Lead discovery #Molecular medicine #Pathology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #System biology #Systems biology #Target validation

The New Blockbuster Drugs – Healthcare packages for particular disease pathologies

The New Blockbuster Drugs – Healthcare packages for particular disease pathologies By Dr Nick Davies and Dr Steve Arlington With the cost of bringing a new drug to market now exceeding $800 million there is no doubt that the pharmaceutical industry has to fundamentally address the way in… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Automation / robotics #Business #Chemistry #Lead discovery #Pharmacology #Regulatory #RNA #System biology #Systems biology #Toxicology

Finding and minding R&D talent the hidden human cost of merger mania

Finding and minding R&D talent the hidden human cost of merger mania By Sue Harris This article examines the impact on R&D staff of the current economic uncertainty, the raft of mega-mergers and the growth of the biotech sector. Senior management repeatedly comment that finding, motivating and retaining… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Flow Cytometry #Gene therapy #Genetics / genomes #High throughput screening #Imaging #Immunology #Molecular medicine #Oncology #Regenerative Medicine #Regulatory #Stem cells #System biology #Systems biology

Stem Cell PHARMACEUTICS

Share Share Tweet Email Stem Cell PHARMACEUTICS Stem Cell PHARMACEUTICS By Dr Gregory G. Lennon Recent research advances in the understanding of stem cell properties are inevitably leading to therapeutic strategies potentially applicable to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Organic chemistry #Pathology #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Predictive chemoinformatics applications to the pharmaceutical industry

Predictive chemoinformatics applications to the pharmaceutical industry By Dr Leslie J. Browne and Laurie L.Taylor While significant advances in chemoinformatics present tremendous opportunities to improve human health, the future of chemoinformatics in the pharmaceutical industry is not without significant challenges. Chemoinformatics is the… Read More

#Archive

#Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Microbiology #Protein chemistry / Proteomics #System biology #Systems biology #Target validation #Toxicology

Protein Biochips – On the threshold of success

Protein Biochips – On the threshold of success By Dr Steven Bodovitz and Felicia Gentile With sales of protein biochips set to top $700 million in 2006, we present a current overview of this fast moving technology and the applications for the pharmaceutical industry as a whole. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Cellular & Molecular biology #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Mass spectrometry / NMR #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics

Proteomatics – New information resources for proteomics

Proteomatics – New information resources for proteomics By Dr David J Parry-Smith and Dr David S Bailey Proteomics is the science of understanding protein architectures at a supramolecular level, whereas the realm of understanding the organisation of biological information in its totality belongs to bioinformatics. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Molecular medicine #PCR #Pharmacogenomics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology

The emergence of pharmacogenomics within the pharmaceutical industry

The emergence of pharmacogenomics within the pharmaceutical industry By Aidan Power, Suzin Webb, Dr Albert Seymour and Dr Patrice Milos The sequencing of the human genome represents one of the most significant scientific advances of the 20th century that will shape the foundation of medical research well… Read More

#Archive

#Analysis #Assay development optimisation & technology #Business #Cellular & Molecular biology #Chemical engineering #Chemistry #Drug development #Flow Cytometry #Genetics / genomes #Genetics / genomics #High throughput screening #Imaging #RNA #Stem cells #System biology #Systems biology #Toxicology

The Once and Future Microarray Market

The Once and Future Microarray Market By Dr Ken Rubenstein Although the future for micorarray technology looks bright, the DNA microarray consumer is faced with a number of important choices regarding sources and technologies. Developers, users, and afficionados of DNA microarray technology, who… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Oncology #Patent Law #Pathology #PCR #Pharmacogenomics #Pharmokinetics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

The importance of using human-based models in gene and drug discovery

The importance of using human-based models in gene and drug discovery By Dr Michael G. Palfreyman, Dr Vinod Charles and Jeffrey Blander Completion of the human genome sequence has opened an unprecedented opportunity to discover the genetic contribution to many of the complex diseases that afflict humans and… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Preclinical #Protein chemistry / Proteomics #RNA #Screening #System biology #Systems biology #Target validation #Toxicology

Benchmarking chemistry functions within pharmaceutical drug discovery and preclinical development

By Dr Roger A. Edwards, Dr Kai Zhang and Louise Firth Different companies have employed various techniques and strategies for addressing productivity issues in the chemistry functions within pharmaceutical discovery and preclinical development. We benchmarked lead optimisation, clinical candidate selection, and chemistry… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Biosecurity #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Molecular medicine #Pathology #Precision medicine #Regulatory #RNA #System biology #Systems biology

Biotechnology, Bioterrorism & Biosecurity

Biotechnology, Bioterrorism & Biosecurity By Dr George Poste Advances in genetics and biotechnology offer great promise in the fight against infectious diseases. But the same technologies will also increase the threat from bioterrorism. Governments must accord ‘biosecurity’ a higher priority in defence and foreign… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Molecular medicine #Pharmacogenomics #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology

High throughput genomics and drug discovery – parallel universes or a continuum?

High throughput genomics and drug discovery – parallel universes or a continuum? By Dr Mark Beggs and Audrey Long HTS has been in place for approximately 10-12 years and has achieved a threeorder of magnitude scale up. Genomics has been in a ‘high throughput’ mode for approximately four… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Microbiology #Molecular medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics

Attacking the SUPERBUGS

By Dr Mark L. Nelson Less than a hundred years ago, if you developed a microbial infection your immune system couldnt handle, you died. Then came the wonder drugs, antibiotics capable of fighting the infections for you. But times have changed. Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Cellular & Molecular biology #Cellular assays #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Pharmacogenomics #Pharmokinetics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics

Chemical microarrays – The drug discovery superhighway

Chemical microarrays – The drug discovery superhighway By Elaine Seeskin While producing targets was once the bottleneck in the drug discovery process, in the post-genomic era this has been superseded by the requirement for high-quality lead structures. As a result of the pool… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Cell culture #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Genetics / genomes #Genomics #High Content Screening #In Silico Biology #Lead discovery #Oncology #Pharmacogenomics #Pharmacology #Regulatory #RNA #System biology #Systems biology #Toxicology

Key R&D informatics challenges facing small/medium-sized pharmaceutical and biotech companiessq

Key R&D informatics challenges facing small/medium-sized pharmaceutical and biotech companies By John Wise The ability of R&D informatics to deliver real benefit to the SME pharmaceutical company is constrained by the increasing burden of non-discretionary computer systems combined with the lack of opportunity to leverage the economies… Read More

#Archive